Telomeric zinc-finger associated protein (TZAP) in cancer biology: friend or foe?

Document Type : Original article

Authors

1 Urology Department, Laboratory of Medical Investigation (LIM55), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil

2 D'Or Institute for Research and Education (IDOR), Sao Paulo, Brazil

3 Minas Gerais State University (UEMG), Passos, Minas Gerais, Brazil

4 Athens University Center (UniAtenas), Passos, Minas Gerais, Brazil

Abstract

The new identified protein telomeric zinc-finger associated protein (TZAP) is a negative regulator of telomere length. Since telomere length and telomere maintenance mechanisms are essential to cancer progression, TZAP is considered a new player in cancer biology. Here we aimed to analyze TZAP using the Cancer Genome Atlas data in a Pan-Cancer approach. We gathering data from TCGA Pan-Cancer studies utilizing cBioPortal, GEPIA and UALCAN. In total we analyzed 33 types of cancer (n=9664) and their respective controls (n=711). TZAP is transcribed in all cancers but less than 5% of all tumors show any somatic changes. TZAP was downregulated in kidney chromophobe carcinoma, and upregulated in esophageal cancer, head and neck squamous cell carcinomas, kidney renal clear cell carcinoma and in liver hepatocellular carcinoma. Globally, TZAP expression is related to favorable prognosis, associated to better overall and disease-free survival. Looking to specific tumors, TZAP expression has a dual behavior. Its downregulation is associated with poor prognosis in cervical squamous cell carcinoma, in kidney renal clear cell carcinoma, kidney papillary cell carcinoma, lung adenocarcinoma and pancreas adenocarcinoma. On the contrary, in adrenocortical carcinoma, colon and rectal cancer, brain lower grade glioma and prostate adenocarcinoma the upregulation of TZAP is related with poor prognosis. TZAP expression has a positive correlation with TRF1 and TRF2 in normal tissue but not in cancer. Our analyses indicate that TZAP has an important role in oncology and may be considered as a potential biomarker.

Keywords

References

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
  2. De Vitis M, Berardinelli F, Sgura A. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT). Int J Mol Sci 2018;19:606.
  3. Yuan X, Dai M, Xu D. Telomere-related markers for cancer. Curr Top Med Chem 2020;20:410-432.
  4. Patel TN, Vasan R, Gupta D, Patel J, Trivedi M. Shelterin proteins and cancer. Asian Pac J Cancer Prev 2015;16:3085-3090.
  5. Luo Z, Liu W, Sun P, Wang F, Feng X. Pan-cancer analyses reveal regulation and clinical outcome association of the shelterin complex in cancer. Brief Bioinform 2021.
  6. Jahn A, Rane G, Paszkowski-Rogacz M, Sayols S, Bluhm A, Han CT, Draskovic I, Londono-Vallejo JA, Kumar AP, Buchholz F, Butter F, Kappei D. ZBTB48 is both a vertebrate telomere-binding protein and a transcriptional activator. EMBO Rep 2017;18: 929-946.
  7. Li JS, Miralles Fusté JM, Simavorian T, Bartocci C, Tsai J, Karlseder J, Denchi EL. TZAP: A telomere-associated protein involved in telomere length control. Science 2017;355:638-641.
  8. Zlotorynski E. Chromosome biology: TZAP trims telomeres. Nat Rev Mol Cell Biol 2017; 18:140.
  9. Donati B, Valenti L. Telomeric zinc-finger associated protein (TZAP): a new player in telomere diseases? Ann Transl Med 2017;5:472.
  10. Jung SJ, Seo YR, Park WJ, Heo YR, Lee YH, Kim S, Lee JH. Clinicopathological Characteristics of TZAP Expression in Colorectal Cancers. Onco Targets Ther 2020;13: 12933-12942.
  11. Park WJ, Park JH, Shin HY, Lee JH. Clinical and prognostic significance of TZAP expression in cervical cancer. Medicina (Kaunas) 2020;56:207.
  12. Heo YR, Lee MH, Kwon SY, Cho J, Lee JH. TZAP mutation leads to poor prognosis of patients with breast cancer. Medicina (Kaunas) 2019;55:748.
  13. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
  14. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
  15. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019;47:W556-W560.
  16. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017;19:649-658.
  17. Bie YN, Gu P, Chen YT, Zhou XX, Tian YG, Yang Q, Li HY, Lin X, Guan YH, Lin TY, Lu X, Shen HF, Fang TX, Liu YM, Xiao D, Gu WW. TZAP plays an inhibitory role in the self-renewal of porcine mesenchymal stromal cells and is implicated the regulation of premature senescence via the p53 pathway. J Transl Med 2019;17:72.
  18. Kim W, Shay JW. Long-range telomere regulation of gene expression: Telomere looping and telomere position effect over long distances (TPE-OLD). Differentiation 2018;99:1-9.
  19. Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett 2018;592:2023-2031.
  20. Wu J, Crowe DL. Telomere DNA damage signaling regulates prostate cancer tumorigenesis. Mol Cancer Res 2020;18:1326-1339.
  21. Montironi R, Cheng L, Scarpelli M, Lopez-Beltran A. Pathology and genetics: Tumours of the urinary system and male genital system: Clinical implications of the 4th edition of the WHO classification and beyond. Eur Urol. 2016;70:120-123.
  22. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010;7:277-285.
  23. Lossaint G, Lingner J. TZAP or not to zap telomeres. Science 2017;355:578-579.
  24. Garcia-Exposito L, O'Sullivan RJ. TZAP-ing telomeres down to size. EMBO Rep 2017;18: 861-863.
  25. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih LM, Donahue CA, Maitra A, Li Q, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu T, Roden RB, Argani P, Marzo AM, Terracciano L, Torbenson M, Meeker AK. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011;179:1608-1615.
  26. Herrmann M, Pusceddu I, März W, Herrmann W. Telomere biology and age-related diseases. Clin Chem Lab Med 2018;56:1210-1222.
  27. Cleal K, Norris K, Baird D. Telomere length dynamics and the evolution of cancer genome architecture. Int J Mol Sci 2018;19:482.
  28. Heo YR, Park WJ, Lee JH. Positive correlation between TZAP and TERT in most cancers: a new player in cancer diseases. Ann Transl Med 2018;6:197.
  29. Donate LE, Blasco MA. Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci 2011;366:76-84.
  30. De Boeck G, Forsyth RG, Praet M, Hogendoorn PC. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 2009; 217:327-344.

Files

Share

How to cite

Statistics